Buy Cipla, Glenmark: Seshadri Bharathan, KSEMA Fincon Ltd
Cipla, Glenmark look very attractive. These companies are exhibiting very strong growth of more than 20% year on year based on global generic and specialty formulations.
By 
|
| Seshadri Bharathan, MD & CEO, KSEMA Fincon Ltd, in a chat with ET Now talks about pharma stocks.
Would you bet on any of the pharma stocks?
Definitely yes. Cipla, Glenmark look very attractive. These companies are exhibiting very strong growth of more than 20% year on year based on global generic and specialty formulations.
The sense that we are getting in Glenmark is that for FY12 the earnings per share would be around Rs 23 and the stock trades at attractive valuations. Same applies for Cipla also. So my sense in pharmaceutical space is Glenmark as well as Cipla buy rating.
Would you bet on any of the pharma stocks?
Definitely yes. Cipla, Glenmark look very attractive. These companies are exhibiting very strong growth of more than 20% year on year based on global generic and specialty formulations.
The sense that we are getting in Glenmark is that for FY12 the earnings per share would be around Rs 23 and the stock trades at attractive valuations. Same applies for Cipla also. So my sense in pharmaceutical space is Glenmark as well as Cipla buy rating.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
Related Articles
Amish proverb of the day: ‘He who has no money is poor; he who has nothing but money is even poorer.’ - a lesson on the wealth that money can't buy2026-06-21T07:15:12Z- Bitcoin remains resilient at $63,600 amid steady ETF inflows and institutional buying2026-06-20T08:08:45Z
- Luxury homes emerge as wealth play? Madhusudan Kela buys apartment at DLF’s The Dahlias2026-06-20T03:42:47Z
ADVERTISEMENT
